Ignite Creation Date:
2025-12-24 @ 4:19 PM
Ignite Modification Date:
2025-12-28 @ 9:39 PM
Study NCT ID:
NCT04075266
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-23
First Post:
2019-08-14
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
Sponsor:
Hoffmann-La Roche
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-01-09
Start Date Type:
ACTUAL
Primary Completion Date:
2023-10-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2029-12-01
Completion Date Type:
ESTIMATED
First Submit Date:
2019-08-14
First Submit QC Date:
None
Study First Post Date:
2019-08-30
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-10-16
Results First Submit QC Date:
None
Results First Post Date:
2024-11-08
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-05
Last Update Post Date:
2025-12-23
Last Update Post Date Type:
ESTIMATED